News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
The data-focused CRO has added Dr. Mike Poole, MD, FACP, to its board of scientific advisors, a role in which he will advise the company on the design, conduct, and reporting of Phase II-IV clinical trials.
Currently a venture partner at Biomatics Capital, Poole most recently led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation.
Additionally, Poole has served as vice president and head of neuroscience innovation at AstraZeneca as well as chief medical officer for Link Medicine and Hypnion. He also was vice president of neuroscience development at Wyeth and Pfizer.